Explore

Autolus Therapeutics Receives FDA RMAT Designation for Obe-cel in Lupus Treatment

Autolus Therapeutics Receives FDA RMAT Designation for Obe-cel in Lupus Treatment

Autolus Therapeutics plc, a biopharmaceutical company, has announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to obecabtagene autoleucel (obe-cel). This designation is specifically for the treatment of systemic lupus erythematosus (SLE) and lupus nephritis (LN). The RMAT designation is a program established under the 21st Century Cures Act, designed to expedite the development and regulatory review process for regenerative medicine therapies, including cell therapies, that are intended to treat serious or life-threatening diseases. Autolus Therapeutics is currently enrolling patients in LUMINA, a pivotal Phase 2 study for obe-cel in refractory lupus nephritis, and expects to report data in 2028. The company also submitted a data update from the Phase 1 CARLYSLE trial for presentation at the American College of Rheumatology (ACR) Annual Meeting in the fourth quarter of 2026.

Atman Health Secures ARPA-H Award to Develop Agentic AI System for Cardiovascular Care

Atman Health Secures ARPA-H Award to Develop Agentic AI System for Cardiovascular Care

Atman Health has been selected by the Advanced Research Projects Agency for Health (ARPA-H) to develop an agentic artificial intelligence system for cardiovascular care, with an initial focus on heart failure. This award is part of ARPA-H's ADVOCATE program, a 39-month initiative aimed at modernizing the management of chronic cardiovascular disease in the United States. The company's AI system is designed to provide continuous patient contact and optimize medication regimens for heart failure patients, addressing the significant gap in specialist access, as nearly half of American counties lack a practicing cardiologist. Atman Health's system separates large language model (LLM) functions for record interpretation and patient communication from clinical decision-making, which is handled by a deterministic engine built on over 9,000 explicit clinical criteria. This approach ensures transparency and auditability of clinical decisions, a critical factor for regulatory approval and physician trust.

Xeris Biopharma Details Comprehensive Development Program for XP-8121, a Once-Weekly Hypothyroidism Treatment

Xeris Biopharma Details Comprehensive Development Program for XP-8121, a Once-Weekly Hypothyroidism Treatment

Xeris Biopharma Details Comprehensive Development Program for XP-8121, a Once-Weekly Hypothyroidism Treatment

Quel Health Launches Telehealth Platform for Addiction Treatment Using GLP-1 Medications

Quel Health Launches Telehealth Platform for Addiction Treatment Using GLP-1 Medications

Santa Fe, N.M.-based startup Quel Health has launched a new telehealth platform designed for addiction treatment, notably incorporating GLP-1 medications. The company asserts this is the first national telehealth service of its kind to utilize GLP-1s for this purpose. The platform offers patients video evaluations, individualized treatment plans, and ongoing care support from affiliated providers. While providers may prescribe GLP-1s off-label when clinically appropriate, it's important to note that the U.S. Food and Drug Administration (FDA) has not yet approved these medications for substance use indications. Over 50 clinical trials are currently registered on ClinicalTrials.gov to examine the use of GLP-1s for addiction. Quel Health was co-founded by epidemiologist Marlene C. Lira and physician-scientist Steven D. Klein, M.D., Ph.D., aiming to provide an accessible, private, and human-centered approach to what they term 'dopamine health.' The platform is currently available in 41 states and Washington, ...

Insilico Medicine's Experimental Drug Shows Potential to Slow Biological Aging in Clinical Study

Insilico Medicine's Experimental Drug Shows Potential to Slow Biological Aging in Clinical Study

Insilico Medicine, a Massachusetts-based AI drug discovery startup, has announced that its experimental drug, rentosertib, developed for idiopathic pulmonary fibrosis (IPF), has shown an unexpected 'bonus' effect of potentially slowing biological aging. In a small clinical study, patients treated with rentosertib exhibited changes in blood proteins that suggested they were biologically younger by an average of three to four years, with some showing a reduction of up to six years. This finding was presented at a Nature conference at Sorbonne University in Paris and published in Nature Biotechnology. The drug, discovered with the aid of artificial intelligence, is currently in a year-long phase 3 study involving over 300 patients in China. Researchers, including Insilico's co-CEO Alex Zhavoronkov, emphasize that these are preliminary findings and do not yet definitively prove the drug can reverse aging or extend life, but they indicate a promising trend in age reversal alongside disease treatment.

Atherosclerosis May Be Classified as an Autoimmune Disease, New Research Suggests

Atherosclerosis May Be Classified as an Autoimmune Disease, New Research Suggests

New research from an international consortium, led by Professor Andreas Habenicht at LMU University Hospital and Professor Changjun Yin at Sun-Yat-Sen University in Guangzhou, China, suggests that atherosclerosis meets key criteria for an autoimmune disease. The study, published in Nature Cardiovascular Research, identifies high-affinity autoreactive antibodies that accelerate atherosclerosis when transferred into mice. One of these autoantibodies targets histone 2B. Further experiments showed that vaccinating mice with histone 2B increased the severity of atherosclerosis. These experimental findings in mice were supported by a clinical trial involving 495 patients from Guangzhou. Autoimmune diseases are characterized by the immune system attacking the body through pathogenic B cells or T cells, leading to organ damage, as seen in conditions like multiple sclerosis, type 1 diabetes, and rheumatoid arthritis. This new evidence proposes a similar mechanism for atherosclerosis, a condition previously not form...

Leyden Labs Reports Positive Phase 1 Results for RIG-101, Advancing Asthma Protection

Leyden Labs Reports Positive Phase 1 Results for RIG-101, Advancing Asthma Protection

Leyden Laboratories B.V. (Leyden Labs) has announced positive results from a Phase 1 study of RIG-101, an investigational intranasal innate immune modulator. RIG-101 is being developed to prevent the consequences of common respiratory viral infections in vulnerable patients, particularly those with asthma. The study demonstrated that RIG-101 was safe and well-tolerated in both healthy volunteers and asthma patients across all dose levels, with up to seven days of daily administration. Biomarker analyses confirmed the activation of the intended antiviral response in the upper respiratory tract, including the induction of type I and type III interferons and interferon-stimulating genes. These findings support the advancement of RIG-101 into Phase 2 clinical development, with the next planned study being a human rhinovirus challenge study in asthma patients. RIG-101 is designed to enhance innate antiviral immune responses in patient populations with impaired natural defenses against respiratory viruses.

ARPA-H Initiates Program to Develop FDA-Authorized Clinical AI for Cardiovascular Care

ARPA-H Initiates Program to Develop FDA-Authorized Clinical AI for Cardiovascular Care

The Advanced Research Projects Agency for Health (ARPA-H) has launched the Agentic AI-EnableD CardioVascular CAre TransfOrmation (ADVOCATE) program, committing up to $33.7 million in its first year. This four-year program, with a total budget of $62.7 million, aims to create the world's first reliable, FDA-authorized clinical agentic AI system for 24/7 cardiovascular care. The goal is to establish a digital member of the clinical care team that can autonomously support heart failure patients between visits and escalate to human care teams when necessary. Selected teams, including Atman Health, Tempus AI, and Updoc, will develop patient-facing clinical AI agents. Stanford University will develop a supervisory AI agent to monitor these clinical agents for safety and out-of-distribution behavior. Duke University and Kaiser Permanente will focus on scalable implementation strategies within health systems, particularly in rural and underserved communities. The program will engage the U.S. Food and Drug Administ...

BrainChild Bio Secures $116 Million Series A Funding to Advance Pediatric Brain Tumor CAR T-Cell Therapy

BrainChild Bio Secures $116 Million Series A Funding to Advance Pediatric Brain Tumor CAR T-Cell Therapy

BrainChild Bio, a biotechnology company, has successfully raised $116 million in Series A financing. This funding is primarily allocated to support the pivotal registrational trial for its lead candidate, BCB-276, an autologous chimeric antigen receptor (CAR) T-cell therapy. BCB-276 is designed to treat diffuse intrinsic pontine glioma (DIPG), a rare and aggressive pediatric brainstem tumor. The current standard of care for DIPG is radiation therapy, which offers limited options. The company has already dosed the first patient in its Phase II ILLUMINATE trial (NCT07680439), an open-label, single-arm study evaluating the efficacy and safety of BCB-276 in children and young adults with newly diagnosed DIPG following initial radiation therapy. The trial aims to accelerate the path to a future biologics license application (BLA) filing for BCB-276, which has received Fast Track designation from the FDA. The primary endpoint for the trial is overall survival, with secondary endpoints including safety, tolerabil...

Global Microbiome Therapeutics Market Projected to Reach $4.6 Billion by 2035 Amidst Clinical and Regulatory Advancements

Global Microbiome Therapeutics Market Projected to Reach $4.6 Billion by 2035 Amidst Clinical and Regulatory Advancements

Global Microbiome Therapeutics Market Projected to Reach $4.6 Billion by 2035 Amidst Clinical and Regulatory Advancements

AI-Generated Drug Candidate Rentosertib Shows Potential for Anti-Aging and Lung Disease Treatment

AI-Generated Drug Candidate Rentosertib Shows Potential for Anti-Aging and Lung Disease Treatment

An AI-generated drug candidate, rentosertib, developed by Insilico Medicine, has demonstrated potential in slowing aging and treating a chronic lung disease. The drug's molecular structure was created with the assistance of artificial intelligence. Clinical trial results, published in Nature Biotechnology, indicate that rentosertib successfully reduced biological markers associated with aging. While these findings are promising, the drug is still several years away from potential regulatory approval. It is important to note that the anti-aging effects of rentosertib have not yet been tested in healthy patients, with current research focusing on its impact on biological markers rather than direct anti-aging outcomes in a broader population. The development highlights the growing role of AI in drug discovery and its potential to accelerate the identification and creation of novel therapeutic compounds for complex conditions.

CRISPR-Cas9 Gene Editing Advances Treatment for Transfusion-Dependent Beta Thalassemia

CRISPR-Cas9 Gene Editing Advances Treatment for Transfusion-Dependent Beta Thalassemia

CRISPR-Cas9 gene editing technology is at the forefront of emerging therapies for transfusion-dependent beta thalassemia. This genetic blood disorder, caused by mutations in the HBB gene, leads to insufficient healthy hemoglobin production, necessitating chronic blood transfusions. Exagamglogene autotemcel, a gene therapy utilizing CRISPR-Cas9, aims to correct this genetic defect by editing a patient's own stem cells. The process involves collecting the patient's stem cells, modifying them in a lab to increase fetal hemoglobin production, and then reinfusing them into the patient. Clinical trials for exagamglogene autotemcel have shown promising results, with a significant majority of participants achieving independence from red blood cell transfusions and reporting improved quality of life. This personalized approach reduces risks associated with donor transplants and offers a potential long-term solution for patients who have historically relied on lifelong symptom management.